Position in DNLI
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$3,652
+$661 QoQ
Shares Held
142
-31.1% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#247
of 290 holders
Holding Since
Mar 2020
10 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026MEEDER ASSET MANAGEMENT INC holds $6,351,882 across 34 Biotechnology names. DNLI ranks #27 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
7,156 | $4,462,048 | |
| 2 | CAI |
Caris Life Sciences, Inc.
|
34,035 | $606,501 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
1,570 | $472,613 | |
| 4 | CLDX |
Celldex Therapeutics, Inc.
|
5,009 | $186,384 | |
| 5 | MNPR |
Monopar Therapeutics
|
1,389 | $128,607 | |
| 6 | RAPP |
Rapport Therapeutics, Inc.
|
2,774 | $115,592 | |
| 7 | CRVS |
Corvus Pharmaceuticals, Inc.
|
6,055 | $90,461 | |
| 8 | ADMA |
Adma Biologics, Inc.
|
8,913 | $74,601 |
All Filings in DNLI
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,652 | 142 | Shares | Sole | 2026-08-07 | |
| 2025-09-30 | $2,991 | 206 | Shares | Sole | 2025-10-24 | |
| 2024-12-31 | $3,362 | 165 | Shares | Sole | 2025-02-12 | |
| 2024-09-30 | $4,631 | 159 | Shares | Sole | 2024-11-07 | |
| 2021-09-30 | $185,098 | 3,669 | Shares | Defined | 2021-11-08 | |
| 2021-06-30 | $215,474 | 2,747 | Shares | Defined | 2021-08-09 | |
| 2021-03-31 | $139,378 | 2,441 | Shares | Defined | 2021-04-28 | |
| 2020-09-30 | $86,922 | 2,426 | Shares | Defined | 2020-11-02 | |
| 2020-06-30 | $11,264 | 466 | Shares | Defined | 2020-08-11 | |
| 2020-03-31 | $26,492 | 1,513 | Shares | Defined | 2020-05-15 | |
| No filing history on record for this holder in this stock. | ||||||